The role of renin-angiotensin-aldosterone system in the progression of chronic kidney
disease The renin-angiotensin-aldosterone system (RAAS) is a well known regulator of …

Abstract The PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine
Impact on Global Mortality and Morbidity in Heart Failure) trial demonstrated that a new …

Background: Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients
with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac …

Bone marrow-derived mesenchymal stem cells (MSCs) have contributed to the improvement
of diabetic nephropathy (DN); however, the actual mediator of this effect and its role has not …

Abstract Sacubitril/valsartan (LCZ696) is recommended for ejection fraction reduction in
heart failure. However, studies comparing the effects of sacubitril/valsartan in patients with …

Progressive deterioration of kidney function in chronic kidney disease (CKD) is mediated by
hypertension, oxidative stress, inflammation, and fibrosis. Renin-angiotensin blockade is …

Despite current practice, patients with chronic kidney disease (CKD) are at increased risk of
progression to end-stage renal disease and cardiovascular events. Neprilysin inhibition …

Heart failure with reduced ejection fraction (HFrEF) is a progressive disorder whereby
cardiac structure and function continue to deteriorate, often despite the absence of clinically …

Twenty-five to 40% of diabetic patients develop diabetic nephropathy, a clinical syndrome
that comprises renal failure and increased risk of cardiovascular disease. It represents the …

Patients with chronic kidney disease (CKD) are often complicated with heart failure with
preserved ejection fraction (HFpEF). However, several drugs, including angiotensin …